1 omized within 16 h to intravenous placebo or
serelaxin.
2 (Likert scale; placebo, 150 patients [26%];
serelaxin,
156 [27%]; p=0.70).
3 Adverse event rates were similar with
serelaxin (
20.5%) and placebo (25.0%).
4 89 mL/min per 1.73 m(2) received intravenous
serelaxin 30 mug/kg per day or placebo for 24 hours.
5 lus 48-h intravenous infusions of placebo or
serelaxin (
30 mug/kg per day) within 16 h from presentat
6 fewer deaths at day 180 (placebo, 65 deaths;
serelaxin,
42; HR 0.63, 95% CI 0.42-0.93; p=0.019).
7 up to day 60 (placebo, 47.7 [SD 12.1] days;
serelaxin,
48.3 [11.6]; p=0.37).
8 vents [60-day Kaplan-Meier estimate, 13.0%];
serelaxin,
76 events [13.2%]; hazard ratio [HR] 1.02 [0.
9 AHF) to evaluate the therapeutic efficacy of
serelaxin,
a recombinant form of human relaxin-2.
10 Serelaxin,
a recombinant form of the naturally occurring
11 Serelaxin administration improved these markers, consist
12 Serelaxin also decreased lipid accumulation in kidney in
13 Renal plasma flow increased by 29% with
serelaxin and 14% with placebo (13% relative increase wi
14 Filtration fraction increased by 36% with
serelaxin and 62% with placebo (16% relative decrease wi
15 rimarily, we assessed the difference between
serelaxin and placebo on renal plasma flow (para-aminohi
16 ential of selective renal vasodilation using
serelaxin as a new treatment for renal dysfunction in ci
17 We hypothesized that
serelaxin could ameliorate renal vasoconstriction and re
18 Treatment of DOCA-salt rats with
serelaxin decreased renal inflammation, including the ex
19 n the randomized clinical study, infusion of
serelaxin for 120 min increased total renal arterial blo
20 with osmotic minipumps delivering vehicle or
serelaxin for another 4 weeks.
21 Serelaxin improved the VAS AUC primary dyspnoea endpoint
22 The renal hemodynamic effects of
serelaxin in patients with chronic heart failure are unk
23 tic targeting of renal vasoconstriction with
serelaxin in the rat models increased kidney perfusion,
24 In patients with chronic heart failure,
serelaxin increased renal plasma flow and reduced the in
25 tients were randomized 1:1 to treatment with
serelaxin intravenous (i.v.) infusion (for 60 min at 80
26 Serelaxin is a promising therapy for acute heart failure
27 1161 patients were randomly assigned to
serelaxin (
n=581) or placebo (n=580).
28 NGS: 1161 patients were randomly assigned to
serelaxin (
n=581) or placebo (n=580).
29 In this study, the effects of
serelaxin on cardiac and renal function, fibrosis, infla
30 ard models were used to assess the effect of
serelaxin on each mode of death, on the basis of pre-spe
31 In the RELAX-AHF study, the effects of
serelaxin on mortality were primarily driven by reductio
32 m of this study was to assess the effects of
serelaxin on short-term changes in markers of organ dama
33 al of this study was to assess the effect of
serelaxin on specific modes of death in patients with AH
34 with AHF to 48 h of therapy with intravenous
serelaxin or placebo.
35 62% with placebo (16% relative decrease with
serelaxin;
P=0.0019) during 8 to 24 hours.
36 14% with placebo (13% relative increase with
serelaxin;
P=0.0386), whereas GFR changes did not differ
37 Treatment with
serelaxin prevented cardiac and renal dysfunction in DOC
38 Serelaxin prevented cardiac and renal fibrosis, as deter
39 Serelaxin (
recombinant human relaxin-2) is a peptide mol
40 Serelaxin,
recombinant human relaxin-2, is a vasoactive
41 Serelaxin reduced 180-day mortality, with similar effect
42 In summary,
serelaxin reversed DOCA-salt induced cardiac and renal d
43 the Treatment of Acute Heart Failure) study,
serelaxin,
the recombinant form of human relaxin-2, redu
44 e RELAX-AHF trial tested the hypothesis that
serelaxin-
treated patients would have greater dyspnoea r
45 There was no apparent impact of
serelaxin treatment on HF deaths or non-CV deaths.
46 Serelaxin treatment was associated with significant redu
47 Serelaxin treatment was well tolerated and safe, support
48 Early administration of
serelaxin was associated with a reduction of 180-day mor
49 Treatment of acute heart failure with
serelaxin was associated with dyspnoea relief and improv
50 ATION: Treatment of acute heart failure with
serelaxin was associated with dyspnoea relief and improv
51 The treatment effect of
serelaxin was most pronounced on other CV deaths (hazard
52 In a pilot study,
serelaxin was safe and well tolerated with positive clin
53 Administration of
serelaxin was safe and well tolerated, with no detriment